KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to $4.3 billion.

  • Gsk's Free Cash Flow rose 163.14% to $4.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.6 billion, marking a year-over-year increase of 2413.08%. This contributed to the annual value of $13.6 billion for FY2025, which is 1465.12% up from last year.
  • As of Q4 2025, Gsk's Free Cash Flow stood at $4.3 billion, which was up 163.14% from $3.8 billion recorded in Q3 2025.
  • Over the past 5 years, Gsk's Free Cash Flow peaked at $4.3 billion during Q4 2025, and registered a low of $632.1 million during Q1 2023.
  • Moreover, its 5-year median value for Free Cash Flow was $3.1 billion (2023), whereas its average is $2.8 billion.
  • In the last 5 years, Gsk's Free Cash Flow skyrocketed by 31757.14% in 2022 and then tumbled by 8402.15% in 2023.
  • Gsk's Free Cash Flow (Quarter) stood at $3.5 billion in 2021, then fell by 2.74% to $3.4 billion in 2022, then fell by 10.37% to $3.0 billion in 2023, then surged by 41.19% to $4.3 billion in 2024, then increased by 1.63% to $4.3 billion in 2025.
  • Its Free Cash Flow stands at $4.3 billion for Q4 2025, versus $3.8 billion for Q3 2025 and $3.6 billion for Q2 2025.